Your search matched 10 results
The answer, it seems, is neither yes nor no, and the panelists at 2019 Digital Medicine and MedTech showcase weighed in from a number of different perspectives.
At this year’s Digital Medicine & MedTech Showcase (part of Biotech Showcase), a panel of digital therapeutics (DTx) experts illuminated the status and future of their work, moderated by Syneos Health Commercial Solutions Chief Strategy Officer, Baba Shetty.
With there being so many different stakeholders, including patients, providers and payers, panelists at the 2019 Digital Medicine & MedTech Showcase pointed to a number of different adoption roadblocks—and successes.
AI: The next great augmentation tool | In The Media
Check out the KNect365 article for a recap of the session at the Digital Medicine & Medtech Showcase luncheon panel moderated by AJ Triano, SVP Engagement Strategy.
Digital therapeutics, or DTx, are distinct from digital health products, and are driven by software programs that can be prescribed to prevent, manage, or treat a medical disorder or disease, as stated by the Digital Therapeutics Alliance.
What healthcare stakeholders should think about when it comes to DTx partnerships and how DTx developers can satisfy diverse stakeholder needs.
Recognizing that the impact of multiple sclerosis (MS) goes beyond the conventionally recognized symptoms, Sanofi has announced a new app to support people with the disease—specifically, their mental health.
Where will digital therapeutics or DTx be in five years?
Syneos Health Releases 2018 Commercial Trends Forecast | In The Media
The Commercial Forecast Joins a Series of Consumer, Digital, Communications and Healthcare Trends Reports that Reveals Shifts in Media and Medicine Impacting Stakeholder Engagement
New Data from Global Survey Reveals Expectations and Concerns of Patients and Caregivers Confronting a Future with Artificial Intelligence